Department of Biotechnology and Genetic Engineering, Faculty of Biological Sciences, Islamic University, Kushtia, Bangladesh.
Department of Statistics, Faculty of Sciences, Islamic University, Kushtia, Bangladesh.
J Biomol Struct Dyn. 2020 Oct;38(16):4850-4867. doi: 10.1080/07391102.2019.1692072. Epub 2019 Nov 20.
is an emerging human pathogen causing neonatal meningitis, catheter-associated infections and nosocomial outbreaks with high mortality rates. Besides, they are resistant to most antibiotics used in empirical therapy. In this study, therefore, we used immunoinformatic approaches to design a prophylactic peptide vaccine against as an alternative preventive measure. Initially, cytotoxic T-lymphocyte (CTL), helper T-lymphocyte (HTL), and linear B-lymphocyte (LBL) epitopes were predicted from the highest antigenic protein. The CTL and HTL epitopes together had a population coverage of 99.97% around the world. Eventually, six CTL, seven HTL, and two LBL epitopes were selected and used to construct a multi-epitope vaccine. The vaccine protein was found to be highly immunogenic, non-allergenic, and non-toxic. Codon adaptation and cloning were performed to ensure better expression within K12 host system. The stability of the vaccine structure was also improved by disulphide bridging. In addition, molecular docking and dynamics simulation revealed strong and stable binding affinity between the vaccine and toll-like receptor 4 (TLR4) molecule. The immune simulation showed higher levels of T-cell and B-cell activities which was in coherence with actual immune response. Repeated exposure simulation resulted in higher clonal selection and faster antigen clearance. Nevertheless, experimental validation is required to ensure the immunogenic potency and safety of this vaccine to control infection in the future.Communicated by Ramaswamy H. Sarma.
是一种新兴的人类病原体,可导致新生儿脑膜炎、导管相关感染和医院感染爆发,死亡率很高。此外,它们对大多数用于经验性治疗的抗生素都有耐药性。因此,在这项研究中,我们使用免疫信息学方法设计了一种针对 的预防性肽疫苗,作为一种替代预防措施。最初,从最高抗原性蛋白中预测了细胞毒性 T 淋巴细胞 (CTL)、辅助性 T 淋巴细胞 (HTL)和线性 B 淋巴细胞 (LBL)表位。CTL 和 HTL 表位的总体人群覆盖率在全球范围内达到了 99.97%。最终,选择了六个 CTL、七个 HTL 和两个 LBL 表位用于构建多表位疫苗。疫苗蛋白被发现具有高度的免疫原性、无变应原性和非毒性。进行密码子适应和 克隆以确保在 K12 宿主系统内更好地表达。通过二硫键桥接提高了疫苗结构的稳定性。此外,分子对接和动力学模拟显示疫苗与 Toll 样受体 4 (TLR4) 分子之间具有强大而稳定的结合亲和力。免疫模拟显示 T 细胞和 B 细胞活性水平更高,与实际免疫反应一致。重复暴露模拟导致更高的克隆选择和更快的抗原清除。然而,需要进行实验验证以确保这种疫苗的免疫原性和安全性,以控制未来 的感染。由 Ramaswamy H. Sarma 传达。